The Brazilian Ministry of Health has incorporated the Fecal Immunochemical Test, known as FIT, into the Sistema Único de Saúde (SUS) for colorectal cancer screening [3].
This expansion of the public health system allows for the early detection of tumors in patients who show no symptoms. Identifying these cases before they become severe is expected to reduce mortality rates associated with the disease [1, 5].
The official announcement of the new protocol occurred around May 21, 2026 [2]. While some reports dated the news to May 22, 2026, the initiative marks a shift toward more proactive screening for the general population [1, 2].
Roberto Gil, the director of the National Cancer Institute, said the details regarding the implementation of the screening process [1]. The FIT test specifically looks for hidden blood in the stool, which can be an early indicator of colorectal malignancy [3].
The screening protocol is specifically targeted at adults between the ages of 50 and 75 [1]. By focusing on this age group, the ministry aims to capture the highest risk demographic for the disease in an asymptomatic state.
Because the test is non-invasive and can be performed without symptoms, it serves as a primary tool to increase the volume of early diagnoses across the country [3, 4]. The integration into the SUS ensures that this diagnostic technology is available to the population regardless of income level [2, 4].
“The FIT test specifically looks for hidden blood in the stool”
The adoption of the FIT test represents a transition from reactive to preventive oncology within Brazil's public health framework. By targeting the 50-75 age bracket with a non-invasive tool, the government can identify precancerous polyps or early-stage tumors that would otherwise go unnoticed until they reached advanced, harder-to-treat stages.
